Supernatural: Delivery of Natural and Biotechnological Actives

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".

Deadline for manuscript submissions: 20 December 2024 | Viewed by 1015

Special Issue Editors


E-Mail Website
Guest Editor
Department of Pharmacy, University of Salerno, Via Giovanni Paolo II 132, I-84084 Fisciano, Italy
Interests: drug delivery; formulation and modified release; natural polymers; polymer science; particle engineering; pharmaceutical application of micro- and nano-technologies; 3D-printing; polymeric scaffolds for tissue engineering
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Pharmacy, University of Salerno, Via Giovanni Paolo II 132, I-84084 Fisciano, SA, Italy
Interests: nanomedicine; small molecules and nucleic-acid-based drug delivery; targeted delivery; theranostic; polymers for biomedical application
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This upcoming Special Issue of Pharmaceutics, entitled "Supernatural: Delivery of Natural and Biotechnological Actives", aims to present recent advances and challenges in the development of formulations and pharmaceutical technologies which maximize the therapeutic potential of natural and biotechnological actives, with a focus on improving the efficacy and safety of these compounds. The Issue will cover topics related to the production, formulation, and delivery of natural ingredients such as herbal and algal extracts, and biotechnological products such as peptides, proteins, and nucleic acids, exploiting various platforms such as emulsions, nanoparticles, liposomes, microspheres, dendrimers, and others. Furthermore, this Special Issue will address the challenges associated with production methods (i.e., extraction, micro-/nano-encapsulation) optimization, stability under and post-processing, and the scale-up of these formulations. The development of safe and effective formulations for the delivery of natural and biotechnological actives is of critical importance in pharmaceutical research in meeting the increasing demand for novel therapies and in improving patient outcomes.

In this Special Issue, we aim to publish both original research articles and reviews. Research areas may include (but are not limited to) the following:

  • Research progress taking place to accomplish targeted delivery of nucleic acid-based drugs;
  • Comparative studies on non-viral vectors for siRNA delivery;
  • Protein and peptide polymer-based delivery systems;
  • Development, characterization, and clinical investigation of new systems containing herbal active extracts;
  • Micro and nanosystems to improve technological and functional properties of bioactive compounds from microalgae extraction.

The ultimate goal of this Special Issue is to provide readers with an up-to-date understanding of the current state of the art in the delivery of natural and biotechnological actives. By highlighting the latest developments and breakthroughs in this field, we hope to inspire researchers and scientists to continue exploring and innovating in this area, and ultimately contribute to the improvement of human health and well-being.

We look forward to receiving your contributions.

Dr. Giulia Auriemma
Dr. Carla Sardo
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • formulation
  • pharmaceutical technology
  • nucleic acid-based drugs
  • gene therapy
  • biotechnological products
  • delivery systems
  • microspheres
  • microalgae
  • natural actives
  • biotechnological actives
  • delivery systems
  • polyplexes
  • microemulsions
  • nanoparticles
  • bioavailability
  • efficacy
  • safety
  • therapeutic potential
  • personal care products
  • diseases
  • solubility
  • stability

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

18 pages, 3181 KiB  
Article
Inulin Amphiphilic Copolymer-Based Drug Delivery: Unraveling the Structural Features of Graft Constructs
by Carla Sardo, Giulia Auriemma, Carmela Mazzacano, Claudia Conte, Virgilio Piccolo, Tania Ciaglia, Marta Denel-Bobrowska, Agnieszka B. Olejniczak, Donatella Fiore, Maria Chiara Proto, Patrizia Gazzerro and Rita Patrizia Aquino
Pharmaceutics 2024, 16(8), 971; https://doi.org/10.3390/pharmaceutics16080971 - 23 Jul 2024
Viewed by 623
Abstract
In this study, the structural attributes of nanoparticles obtained by a renewable and non-immunogenic “inulinated” analog of the “pegylated” PLA (PEG-PLA) were examined, together with the potential of these novel nanocarriers in delivering poorly water-soluble drugs. Characterization of INU-PLA assemblies, encompassing critical aggregation [...] Read more.
In this study, the structural attributes of nanoparticles obtained by a renewable and non-immunogenic “inulinated” analog of the “pegylated” PLA (PEG-PLA) were examined, together with the potential of these novel nanocarriers in delivering poorly water-soluble drugs. Characterization of INU-PLA assemblies, encompassing critical aggregation concentration (CAC), NMR, DLS, LDE, and SEM analyses, was conducted to elucidate the core/shell architecture of the carriers and in vitro cyto- and hemo-compatibility were assayed. The entrapment and in vitro delivery of sorafenib tosylate (ST) were also studied. INU-PLA copolymers exhibit distinctive features: (1) Crew-cut aggregates are formed with coronas of 2–4 nm; (2) a threshold surface density of 1 INU/nm2 triggers a configuration change; (3) INU surface density influences PLA core dynamics, with hydrophilic segment stretching affecting PLA distribution towards the interface. INU-PLA2NPs demonstrated an outstanding loading of ST and excellent biological profile, with effective internalization and ST delivery to HepG2 cells, yielding a comparable IC50. Full article
(This article belongs to the Special Issue Supernatural: Delivery of Natural and Biotechnological Actives)
Show Figures

Graphical abstract

Back to TopTop